Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients

Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients

BackgroundKidney transplant recipients (KTR) are at increased risk of cancer due to chronic immunosuppression. Non-melanoma skin cancer has an excess risk of approximately 250 times higher than the general population. Moreover, in solid organ transplant recipients (SOTR) these cancers have a more ag...

Full description

Bibliographic Details
Main Authors:	T. Van Meerhaeghe, J.F. Baurain, O. Bechter, C. Orte Cano, V. Del Marmol, A. Devresse, P. Doubel, M. Hanssens, R. Hellemans, D. Lienard, A. Rutten, B. Sprangers, A. Le Moine, S. Aspeslagh
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-10-01
Series:	Frontiers in Nephrology
Subjects:	cemiplimab kidney transplant recipients cutaneous squamous cell carcinoma immune checkpoint inhibitors rejection
Online Access:	https://www.frontiersin.org/articles/10.3389/fneph.2022.1041819/full

Similar Items

Corrigendum: Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients
by: T. Van Meerhaeghe, et al.
Published: (2023-01-01)

Rapid response to cemiplimab for advanced cutaneous squamous cell carcinoma
by: Hanieh Zargham, MD, et al.
Published: (2022-08-01)

IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab
by: Domenico Mallardo, et al.
Published: (2023-02-01)

Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center
by: Nerina Denaro, et al.
Published: (2023-09-01)

Safe Administration of Cemiplimab to a Kidney Transplant Patient with Locally Advanced Squamous Cell Carcinoma of the Scalp
by: Luca Paoluzzi, et al.
Published: (2021-01-01)

Real-Life Study of the Benefit of Concomitant Radiotherapy with Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma (cSCC): A Retrospective Cohort Study
by: Barbara Bailly-Caillé, et al.
Published: (2023-01-01)

Desensitization Protocol for Cemiplimab-Related Infusion Reaction in Cutaneous Squamous Cell Carcinoma: A Case Report and Literature Review
by: Marco Banini, et al.
Published: (2023-07-01)

Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access ProtocolResearch in context
by: Karlijn Verkerk, et al.
Published: (2024-04-01)

Intravascular squamous cell carcinoma treated with cemiplimab
by: Alexander N. Rose, BS, et al.
Published: (2021-08-01)

Cemiplimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma: Appropriate Patient Selection and Perspectives
by: Mager L, et al.
Published: (2023-08-01)

Anti‐PD‐1 therapy using cemiplimab for advanced cutaneous squamous cell carcinoma in HIV patient: A case report
by: Abdurahman Alloghbi, et al.
Published: (2021-12-01)

Effective Management of Nasal Vestibule Squamous Cell Carcinoma with Cemiplimab: A Case Report
by: Ferdinando Costabile, et al.
Published: (2023-09-01)

Advanced Squamous Cell Carcinoma Developed on Chronic Hidradenitis Suppurativa, Successfully Treated with Cemiplimab: A Case Report
by: Angelo Ruggiero, et al.
Published: (2023-02-01)

Cemiplimab and Cutaneous Squamous Cell Carcinoma: From Bench to Bedside
by: D.T. Goodman
Published: (2022-09-01)

Real-World Experience with Cemiplimab Treatment for Advanced Cutaneous Squamous Cell Carcinoma—A Retrospective Single-Center Study
by: Daniella Kuzmanovszki, et al.
Published: (2023-09-01)

Risk Factors of Rejection in Renal Transplant Recipients: A Narrative Review
by: Hani Oweira, et al.
Published: (2022-03-01)

Can Cemiplimab Become a Life-Changer in Xeroderma Pigmentosum?
by: Maria Boziou, et al.
Published: (2023-07-01)

A Case of sustained complete response of advanced cutaneous Squamous Cell Cancer of the scalp to Cemiplimab
by: Gogo-ogute E. Ibodeng, et al.
Published: (2023-03-01)

Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group
by: Candice Hober, et al.
Published: (2021-07-01)

Case Report: Autoimmune Pemphigus Vulgaris in a Patient Treated With Cemiplimab for Multiple Locally Advanced Cutaneous Squamous Cell Carcinoma
by: Rosalba Buquicchio, et al.
Published: (2021-08-01)

PD-1 Inhibitors in Elderly and Immunocompromised Patients with Advanced or Metastatic Cutaneous Squamous Cell Carcinoma
by: Alexander Yakobson, et al.
Published: (2023-08-01)

The High-Resolution Structure Reveals Remarkable Similarity in PD-1 Binding of Cemiplimab and Dostarlimab, the FDA-Approved Antibodies for Cancer Immunotherapy
by: Tae-Jun Jeong, et al.
Published: (2022-12-01)

Complete and early response to cemiplimab associated to severe immune toxicity in advanced cervical cancer: a case report
by: Anna Passarelli, et al.
Published: (2023-12-01)

PD-1 N58-Glycosylation-Dependent Binding of Monoclonal Antibody Cemiplimab for Immune Checkpoint Therapy
by: Dan Lu, et al.
Published: (2022-03-01)

[Artículo traducido] Cemiplimab en el carcinoma de células escamosas cutáneo avanzado: experiencia del mundo real en un centro oncológico monográfico
by: E. Ríos-Viñuela, et al.
Published: (2022-06-01)

Cost-effectiveness of cemiplimab plus chemotherapy versus chemotherapy for the treatment of advanced non-small cell lung cancer
by: Xueyan Liang, et al.
Published: (2023-04-01)

Cemiplimab as First Line Therapy in Advanced Penile Squamous Cell Carcinoma: A Real-World Experience
by: Keren Rouvinov, et al.
Published: (2023-11-01)

Association of the Co-stimulatory Molecules Polymorphisms with CMV Infection in Liver Transplant Recipients
by: M. H. Karimi, et al.
Published: (2011-10-01)

Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer
by: Yitian Lang, et al.
Published: (2024-02-01)

Pregnancy outcome in renal transplant recipients: Indian scenario
by: Vineet V Mishra, et al.
Published: (2016-01-01)

Cutaneous alternariosis in a renal transplant recipient: A case report and literature review
by: Chia-Chi Hsu, et al.
Published: (2015-01-01)

Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab—Real-World Experience in the Global SARS-CoV-2 Pandemic
by: Marta Pabianek, et al.
Published: (2022-10-01)

The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer
by: Tingting Lu, et al.
Published: (2023-07-01)

The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?
by: Brazel D, et al.
Published: (2023-06-01)

A Retrospective Study of Cemiplimab Effectiveness in Elderly Patients with Squamous Cell Carcinoma of the Skin: Insights from a Real-Life Scenario
by: Giuseppe Di Lorenzo, et al.
Published: (2023-12-01)

Bullous pemphigoid associated with cemiplimab therapy in a patient with locally advanced cutaneous squamous cell carcinoma
by: Cesar A. Virgen, MD, PhD, et al.
Published: (2020-03-01)

Bilateral Diffuse Uveal Melanocytic Proliferation in a Woman with Metastatic Scalp Squamous Cell Carcinoma Treated with Cemiplimab
by: Etti Katzburg, et al.
Published: (2021-12-01)

Supraorbital Basosquamous Carcinoma Treated with Cemiplimab Followed by Sonidegib: A Case Report and Review of the Literature
by: Ilaria Proietti, et al.
Published: (2023-10-01)

Pembrolizumab vs cemiplimab for the treatment of advanced non-small cell lung cancer with PD-L1 expression levels of at least 50%: A network meta-analysis and cost-effectiveness analysis
by: Yan Li, et al.
Published: (2022-09-01)

Clinical characteristics and immunosuppression management in kidney transplant recipients infected with severe acute respiratory syndrome coronavirus 2 infection - An observational study
by: Kiruthika Somasundaram, et al.
Published: (2022-01-01)